CBioinformatics
cBioinformatics is a Japanese company founded in 2019, specializing in genomic medicine. The company's core offering is a comprehensive genomic analysis platform designed to support precision medicine in cancer treatment. They leverage whole-genome analysis to identify disease risks, suitable drugs, and clinical trial candidates. Their services include 'Cゲノム' for disease risk assessment, 'Cancerゲノム' for identifying therapeutic targets in cancer patients, and 'Cゲノム「仁」' for exploring the causes of rare and intractable diseases. cBioinformatics also provides a drug discovery service utilizing AI-powered virtual screening to accelerate the development of new drugs. The company was founded by a medical doctor and emphasizes the clinical and medical significance of its genomic interpretations.
CBioinformatics
cBioinformatics is a Japanese company founded in 2019, specializing in genomic medicine. The company's core offering is a comprehensive genomic analysis platform designed to support precision medicine in cancer treatment. They leverage whole-genome analysis to identify disease risks, suitable drugs, and clinical trial candidates. Their services include 'Cゲノム' for disease risk assessment, 'Cancerゲノム' for identifying therapeutic targets in cancer patients, and 'Cゲノム「仁」' for exploring the causes of rare and intractable diseases. cBioinformatics also provides a drug discovery service utilizing AI-powered virtual screening to accelerate the development of new drugs. The company was founded by a medical doctor and emphasizes the clinical and medical significance of its genomic interpretations.